



Advanced
Bio-
Circular
Materials


The Arkema Approach To The Sustainability Journey

Guido M Donà
Director, Sustainability Strategy
Specialty Polyamides - High Performance Polymers

World Bio Markets Conference
Barcelona, June 8, 2022



Arkema in a nutshell: Sustainable innovation is in our DNA



Strong recognition from the Sustainability Community

Member of
Dow Jones Sustainability Indices
Powered by the S&P Global CSA


ecovadis



High Performance Polymers

KYNAR®
High-performance
fluoropolymers

RILSAN®
Polyamide 11
100% biobased



KEPSTAN®
Ultra-high performance
PEKK

PEBAX®
High-performance
Elastomer
35-95% biobased



Arkema to start up
new bio-based
polyamide 11 plant
in Singapore in 2022

€450 million investment

Arkema has
successfully placed its
inaugural €300 million
Green Bond





A Journey
We Make Together

The 4 Pillars of our Sustainability Strategy



Recycling



Bio-based
Building Blocks

Castor


Since 1947!




« Low Carbon »
Materials



From castor bean to advanced polymers – A miracle of science



Castor – The magic bean – A renewable feedstock



Castor in India – A Unique Eco-System



80% of the world's castor is grown in Gujarat, India



700 000 farmers grow castor in the region



Driving sustainable castor farming through a continuous improvement program

3 Axes

- Environmental
- Social
- Economic

PRAGATI
A Living Case Study
Started in 2016



End of 2021

+5,800 farmers trained, audited and certified in 69 villages in North Gujarat.

Yield

+35% In year 5, yield is 35% higher than the yield published by government of Gujarat

Water

-35% Water consumption has been lowered compared to the demo plots where water utilization is monitored

Recycling: the time is now

AGIPLAST®

WE RECYCLE ADVANCED PLASTICS

Feeding the loop



Partially or fully
recycled materials



Towards a Low Carbon Environment

Our Commitment

Paris Agreement

→ Scope 1&2

Be part of our customers journey

→ Scope 3

Our Objectives

2030 CO₂eq emissions target*:
-38% vs 2015 absolute emissions
(scope 1&2 + ODS)

Offer Low CF materials
Measurable impact: ISO14067


Roadmap

Working on impactful solutions

- Energy efficiency & renewable energy
- Process optimization & innovation
- Raw Materials with reduced CF

Bio-Building Blocks for our Polymers

→ We explore the whole landscape searching for sustainable innovation



The ABC Materials adventure



// We make this shoe out of beans.
It seems like magic...
but in fact, it is science. //

The Cloudneo running shoe. An elite-level shoe that's high-performance, 100% recyclable and zero waste

ADVANCED BIO-CIRCULAR MATERIALS

THE CIRCLE OF LIFE MEETS THE CIRCULAR ECONOMY



Keynote address - June 9, @11:30
Going Beyond: Achieving High Performance
through bio-based circularity

Nils Altrogge – On Running
Charlotte Herdt – Arkema

Thank You

Let's grow together!



arkema.com

© Copyright 2022 Arkema – All rights reserved. Do not copy without express permission from Arkema.

Virtucycle®, Agiplast®, Agimid®, Agiflex®, Kynar®, Pebax®, Rilsan®, and Rilsamid® are registered trademarks of Arkema.

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications that are in contact with the body or circulating bodily fluids:

<http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html> Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as Medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices. It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies) It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

ARKEMA